<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/355" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/355/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/355/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_355"><akn:num>355</akn:num><akn:heading>New drugs</akn:heading><akn:content><akn:p>§ 355. New drugs(a) Necessity of effective approval of applicationNo person shall introduce or deliver for introduction into interstate commerce any new drug, unless an approval of an application filed pursuant to subsection (b) or (j) is effective with respect to such drug.


(b) Filing application; contents(1)(A) Any person may file with the Secretary an application with respect to any drug subject to the provisions of subsection (a). Such persons shall submit to the Secretary as part of the application—(i) full reports of investigations which have been made to show whether such drug is safe for use and whether such drug is effective in use;

(ii) a full list of the articles used as components of such drug;

(iii) a full statement of the composition of such drug;

(iv) a full description of the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug;

(v) such samples of such drug and of the articles used as components thereof as the Secretary may require;

(vi) specimens of the labeling proposed to be used for such drug;

(vii) any assessments required under section 355c of this title; and

(viii) the patent number and expiration date of each patent for which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug, and that—(I) claims the drug for which the applicant submitted the application and is a drug substance (active ingredient) patent or a drug product (formulation or composition) patent; or

(II) claims a method of using such drug for which approval is sought or has been granted in the application.



(B) If an application is filed under this subsection for a drug, and a patent of the type described in subparagraph (A)(viii) is issued after the filing date but before approval of the application, the applicant shall amend the application to include the patent number and expiration date.


(2)</akn:p></akn:content><akn:subsection eId="subsec_355_a"><akn:num>(a)</akn:num><akn:heading>Necessity of effective approval of application</akn:heading><akn:content><akn:p>(a) Necessity of effective approval of application No person shall introduce or deliver for introduction into interstate commerce any new drug, unless an approval of an application filed pursuant to subsection (b) or (j) is effective with respect to such drug.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_b"><akn:num>(b)</akn:num><akn:heading>Filing application; contents</akn:heading><akn:content><akn:p>(b) Filing application; contents</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_c"><akn:num>(c)</akn:num><akn:heading>Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order</akn:heading><akn:content><akn:p>(c) Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_d"><akn:num>(d)</akn:num><akn:heading>Grounds for refusing application; approval of application; “substantial evidence” defined</akn:heading><akn:content><akn:p>(d) Grounds for refusing application; approval of application; “substantial evidence” defined If the Secretary finds, after due notice to the applicant in accordance with subsection (c) and giving him an opportunity for a hearing, in accordance with said subsection, that (1) the investigations, reports of which are required to be submitted to the Secretary pursuant to subsection (b), do not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof; (2) the results of such tests show that such drug is unsafe for use under such conditions or do not show that such drug is safe for use under such conditions; (3) the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug are inadequate to preserve its identity, strength, quality, and purity; (4) upon the basis of the information submitted to h</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_e"><akn:num>(e)</akn:num><akn:heading>Withdrawal of approval; grounds; immediate suspension upon finding imminent hazard to public health</akn:heading><akn:content><akn:p>(e) Withdrawal of approval; grounds; immediate suspension upon finding imminent hazard to public health The Secretary shall, after due notice and opportunity for hearing to the applicant, withdraw approval of an application with respect to any drug under this section if the Secretary finds (1) that clinical or other experience, tests, or other scientific data show that such drug is unsafe for use under the conditions of use upon the basis of which the application was approved; (2) that new evidence of clinical experience, not contained in such application or not available to the Secretary until after such application was approved, or tests by new methods, or tests by methods not deemed reasonably applicable when such application was approved, evaluated together with the evidence available to the Secretary when the application was approved, shows that such drug is not shown to be safe for use under the conditions of use upon the basis of which the application was approved; or (3) on the</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_f"><akn:num>(f)</akn:num><akn:heading>Revocation of order refusing, withdrawing or suspending approval of application</akn:heading><akn:content><akn:p>(f) Revocation of order refusing, withdrawing or suspending approval of application Whenever the Secretary finds that the facts so require, he shall revoke any previous order under subsection (d) or (e) refusing, withdrawing, or suspending approval of an application and shall approve such application or reinstate such approval, as may be appropriate.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_g"><akn:num>(g)</akn:num><akn:heading>Service of orders</akn:heading><akn:content><akn:p>(g) Service of orders Orders of the Secretary issued under this section shall be served (1) in person by any officer or employee of the department designated by the Secretary or (2) by mailing the order by registered mail or by certified mail addressed to the applicant or respondent at his last-known address in the records of the Secretary.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_h"><akn:num>(h)</akn:num><akn:heading>Appeal from order</akn:heading><akn:content><akn:p>(h) Appeal from order An appeal may be taken by the applicant from an order of the Secretary refusing or withdrawing approval of an application under this section. Such appeal shall be taken by filing in the United States court of appeals for the circuit wherein such applicant resides or has his principal place of business, or in the United States Court of Appeals for the District of Columbia Circuit, within sixty days after the entry of such order, a written petition praying that the order of the Secretary be set aside. A copy of such petition shall be forthwith transmitted by the clerk of the court to the Secretary, or any officer designated by him for that purpose, and thereupon the Secretary shall certify and file in the court the record upon which the order complained of was entered, as provided in section 2112 of title 28. Upon the filing of such petition such court shall have exclusive jurisdiction to affirm or set aside such order, except that until the filing of the record the</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_i"><akn:num>(i)</akn:num><akn:heading>Exemptions of drugs for research; discretionary and mandatory conditions; direct reports to Secretary</akn:heading><akn:content><akn:p>(i) Exemptions of drugs for research; discretionary and mandatory conditions; direct reports to Secretary</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_j"><akn:num>(j)</akn:num><akn:heading>Abbreviated new drug applications</akn:heading><akn:content><akn:p>(j) Abbreviated new drug applications</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>